Skip to main content
A New Era in Biosimilar Access
MedImpact now offers an unbranded biosimilar to Stelara® (ustekinumab) and Humira® (adalimumab) to any licensed pharmacy in the U.S. at up to 95% less than the reference products.

This Changes Everything

Industry-wide access

These products are available for purchase by any licensed pharmacy. This is a significant departure from the common industry practice of selling private-label versions through exclusive arrangements with select pharmacies.

Clinical credibility and interchangeability

Because both of these biosimilars are FDA-designated interchangeable with the reference products, they are likely to result in greater provider and patient acceptance.

Greater transparency

In a step toward freeing the industry from its longstanding dependence on rebates, payers and members will benefit from the lowest cost at point of sale.

A lifeline to pharmacies

By providing industry-wide access to this low cost, commonly prescribed drug, this approach has the potential to be a lifeline to struggling independent pharmacies.

No compromises

At MedImpact, we are committed to providing savings without compromising access, and these launches are another example of how we are delivering on that promise. They also highlight how we are driving lower costs, greater transparency, and change across the industry through innovation and bold thinking.   

 

Pharmacies interested in purchasing these biosimilars can visit the Birdi, Inc. distribution site. 

 

Interested in learning more? Fill out the short form below and a representative will reach out to you shortly. 

AFFORDABILITY AND ACCESS

At MedImpact, we believe that pharmacies are critical to better patient care.

That's why our unbranded biosimilar strategy was designed to not only deliver low-cost medications– but also ensure that these therapies are available to any licensed specialty pharmacy in the nation.

Contact Us to Learn More